Actos Bladder Cancer Lawsuit
Actos attorneys clash with plaintiffs on behalf of consolidated litigation

Actos, a type 2 diabetes medication often used instead Avandia, has been linked to bladder cancer. This once a day pill was approved in July 1999 and has generated $4.3 billion in sales for Takeda Pharmaceuticals, the makers of the drug. During a 10 year study, users who have taken the drug for long periods (greater than one year) of time have experienced an increased risk in bladder cancer. The Food and Drug Administration (FDA) began investigations in September 2010. By June 2011, France issued an Actos recall contributing it to an increased number of reported bladder cancer cases caused by Actos.

On July 29, 2011, the first Actos lawsuit was filed with accusations that the company did not thoroughly research the medication nor did it properly warn about the risks. Actos attorneys deny the allegations but are now aware of 54 cases filed in federal district courts throughout the United States.

It is said that the number of reported Actos bladder cancer cases is expected to grow as more people become aware of the potential side effects.

Currently, Actos attorneys are in the process of making a decision regarding the location for pretrial litigation. Takeda requested that the cases get transferred to the Northern District of Illinois or the Western District of Louisiana but prefer Actos litigation to occur at their headquarters in the Northern District of Illinois while many plaintiffs propose that the U.S. District Judges preside over the litigation. By December 1, the U.S. Judicial Panel on Multidistrict Litigation is expected to schedule oral arguments on the motion to consolidate the cases.


About the Contributor

Related Posts